EP3494109A1 - Verfahren zur herstellung von spiroketal-substituierten cyclischen ketoenolen - Google Patents

Verfahren zur herstellung von spiroketal-substituierten cyclischen ketoenolen

Info

Publication number
EP3494109A1
EP3494109A1 EP17749168.5A EP17749168A EP3494109A1 EP 3494109 A1 EP3494109 A1 EP 3494109A1 EP 17749168 A EP17749168 A EP 17749168A EP 3494109 A1 EP3494109 A1 EP 3494109A1
Authority
EP
European Patent Office
Prior art keywords
compounds
methyl
xvi
xvii
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17749168.5A
Other languages
German (de)
English (en)
French (fr)
Inventor
Thomas Himmler
Julia Johanna HAHN
Joachim CREDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer CropScience AG
Original Assignee
Bayer CropScience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer CropScience AG filed Critical Bayer CropScience AG
Publication of EP3494109A1 publication Critical patent/EP3494109A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system

Definitions

  • the invention relates to a novel process for preparing spiroketal-substituted cyclic ketoenols which can be used as insecticides, acaricides or herbicides.
  • novel intermediates for the preparation of spiroketal- substituted cyclic ketoenols are provided by the present invention.
  • the present invention thus comprises a novel process (B) for the preparation of spiroketal-substituted cyclic ketoenols of the general formula (XI), characterized in that in the first step (1) of the process spiroketal-substituted amino acids of the general formula (III)
  • R 1 to R 6 are independently hydrogen, methyl, ethyl or phenyl and n is 0 or 1 in the presence of a base with a phenylacetic acid chloride of the general formula (VII)
  • radicals R 8 to R 12 independently of one another represent hydrogen, methyl, ethyl, fluoroalkyl having one or 2 C atoms and one to five fluorine atoms, halogen, methoxy, ethoxy, trifluoromethoxy or optionally methyl, ethyl, Methoxy, ethoxy or halogen substituted phenyl, to compounds of general formula (XV)
  • R 1 to R 6 and R 8 to R 12 have the meanings given above, is reacted; then in the second step (2) of the process (B) according to the invention a compound of the general formula (XV) with an a, ra-diol of the general formula (XIV)
  • n and the radicals R 1 to R 6 and R 8 to R 12 have the meanings given above and both n and the corresponding radicals R 1 to R 6 and R 8 to R 12 at both positions of the compounds of the general formulas (XVI) or (XVII) are identical, esterified; then in the third step (3) of the process (B) according to the invention, the compounds of the general formulas (XVI) and (XVII) in which n and the radicals R 1 to R 6 and R 8 to R 12 have the meanings given above, by reaction with a strong base to the spiroketal-substituted cyclic ketoenols of the general formula (XI)
  • R 1 to R 6 is R 1 , R 2 , R 3 , R 4 , R 5 , R 6 .
  • R 8 to R 12 is R 8 , R 9 , R 10 , R 11 , R 12 .
  • R 1 to R 6 independently of one another are preferably hydrogen, methyl or ethyl
  • R 8 to R 12 independently of one another preferably represent hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, ethoxy, trifluoromethoxy or phenyl which is optionally substituted by methyl, ethyl, methoxy, ethoxy, fluorine, chlorine or bromine
  • n is preferably 0 or 1
  • R 1 to R 6 independently of one another particularly preferably represent hydrogen or methyl
  • R 8 to R 12 independently of one another particularly preferably represent hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, ethoxy or phenyl which is optionally substituted by methyl, ethyl, methoxy, ethoxy, fluorine or chlorine, n particularly preferably 0 or 1;
  • R 3 to R 6 independently of one another are likewise particularly preferably hydrogen or methyl,
  • R 8 to R 12 independently of one another are likewise particularly preferably hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, ethoxy or phenyl which is optionally substituted by methyl, methoxy, fluorine or chlorine, n is also particularly preferably 0; R 3 to R 6 independently of one another very particularly preferably represent hydrogen or methyl,
  • R 8 to R 12 independently of one another very particularly preferably represent hydrogen, methyl or chlorine, n very particularly preferably 0.
  • N is 0, R 3 to R 6 are hydrogen, R 8 is methyl, R 9 is hydrogen, R 10 is chlorine, R 11 is hydrogen, R 12 is methyl. N is 0, R 3 to R 6 are hydrogen, R 8 is methyl, R 9 is hydrogen, R 10 is methyl, R 11 is hydrogen, R 12 is methyl.
  • N is 0, R 3 is hydrogen, R 4 is methyl, R 5 is hydrogen, R 6 is methyl, R 8 is methyl, R 9 is hydrogen, R 10 is hydrogen, R 11 is methyl, R 12 is hydrogen ,
  • N is 1, R 1 is hydrogen, R 2 is hydrogen, R 3 is methyl, R 4 is methyl, R 5 is hydrogen, R 6 is hydrogen, R 8 is methyl, R 9 is hydrogen, R 10 is chlorine , R 11 for
  • N is 1, R 1 to R 6 are hydrogen, R 8 is methyl, R 9 is hydrogen, R 10 is chlorine, R 11 is hydrogen, R 12 is methyl.
  • R 1 , R 2 , R 4 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , R 12 and n are as defined above.
  • R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , R 12 and n are as defined above and R 7 is Ci-Ce-alkyl. Particularly emphasized is n for 0; R 3 to R 6 are hydrogen; R 8 and R 12 are methyl; R 9 and R 11 are hydrogen; R 10 is chlorine and R 7 is methyl:
  • R 7 is C 1 -C 6 -alkyl. Particularly noteworthy is R 7 is methyl: C- 0 ⁇ - ⁇ H 2
  • the first stage (1) of the process (B) according to the invention is carried out in a solvent which is inert under the reaction conditions.
  • a solvent for example in question: dichloromethane, toluene, ortho-, meta or para-xylene, mesitylene, chlorobenzene, ortho-dichlorobenzene, acetonitrile, butyronitrile, N, N-dimethylformamide, N, N-dimethylacetamide, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl- methyl ether, methyl tert-butyl ether, tertiary amyl methyl ether, 1,4-dioxane, ethyl acetate, butyl acetate, water or mixtures of these solvents.
  • organic bases such as trimethylamine, triethylamine, piperidine, morpholine, pyridine; or inorganic bases such as ammonia, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, calcium carbonate. Preference is given to sodium hydroxide and potassium hydroxide.
  • Solid inorganic bases can be used as solids or in the form of their aqueous solutions. Preference is given to using aqueous solutions.
  • the base is usually used in an amount such that a pH of between 10 and 14 results. Preference is given to working at a pH of between 11 and 13.
  • the first stage (1) of the process (B) according to the invention is carried out at temperatures between -5 and 50 ° C; preferably between 0 and 30 ° C.
  • the isolation of the compounds of general formula (XV) is carried out by known conventional methods of organic chemistry such as filtration, phase separation or extraction.
  • inert solvents can be used under the reaction conditions.
  • suitable solvents are, for example: dichloromethane, toluene, ortho, meta or para-xylene, mesitylene, chlorobenzene, ortho-dichlorobenzene, acetonitrile, butyronitrile, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentylmethyl ether, methyl tertiarybutyl ether, tertiary amyl methyl ether, 1,4-dioxane or mixtures of these solvents.
  • toluene ortho, meta or para-xylene, chlorobenzene, acetonitrile, butyronitrile, 2-methyl-tetrahydrofuran, cyclopentyl methyl ether, methyl tert-butyl ether, tertiary amyl methyl ether or mixtures of these solvents.
  • the a, ra-diol of the general formula (XIV) is used in an amount of at least 0.5 mol, based on 1 mol of the compound of the general formula (XV). It is also possible in one to work any excess of a, ra-diol of the general formula (XIV) and thus to use this at the same time as a solvent.
  • the second stage (2) of the process (B) according to the invention is carried out in the presence of a catalytic amount of an acid.
  • suitable acids are: hydrogen chloride, sulfuric acid, methanesulfonic acid, trifluoromethanesulfonic acid, para-toluenesulfonic acid or acidic ion exchange resins such as, for example, amberlite.
  • Sulfuric acid or para-toluenesulfonic acid is preferably used. Particular preference is given to using sulfuric acid.
  • the acid is used in amounts of from 0.01 to 20% by weight, based on the compound of the general formula (XV). Preference is given to 0.05 to 10 percent by weight.
  • the second stage (2) of the process (B) according to the invention is carried out at temperatures between 20 and 150 ° C; preferably between 50 and 120 ° C.
  • inert solvents can be used under the reaction conditions.
  • suitable solvents are, for example: toluene, ortho, meta or para-xylene, mesitylene, chlorobenzene, ortho-dichlorobenzene, acetonitrile, butyronitrile, tetrahydrofuran, 2-methyl-tetrahydrofuran, cyclopentyl methyl ether, methyl tert-butyl ether, Tertiary-methyl-ether, 1, 4-dioxane, N, N-dimethylformamide, ⁇ , ⁇ -dimethylacetamide, N-methylpyrrolidone, methanol, ethanol, 1-butanol, tertiary butanol or mixtures of these solvents.
  • Preference is given to N, N-dimethylformamide, ⁇ , ⁇ -dimethylacetamide, N-methylpyrrolidone, methanol, tert
  • sodium hydroxide, potassium hydroxide, sodium methoxide, potassium methoxide, sodium ethylate, potassium ethylate, sodium tertiary butylate or potassium tertiary butylate can be used.
  • the bases are used in an amount of 0.9 to 4 molar equivalents, based on the compounds of the general formulas (XVI) and (XVII). It is preferable to use 1 to 3.5 molar equivalents.
  • the temperature in the third step (3) of the process (B) according to the invention is between 20 and 150 ° C. Preference is given to working between 40 and 100 ° C.
  • the compounds of the formula (III) are known in some cases (WO 06/089633), some new or can be prepared by the processes described therein.
  • the compounds of the formula (VII) are known in some cases (WO 97/02243), in some cases new or can be prepared by the processes described therein.
  • the compounds of the formula (XIV) are commercially available.
  • WO 06/089633 describes the preparation of the compound 8-amino-1,4-dioxaspiro [4.5] decane-8-carboxylic acid (III-1) by boiling the compound 9,12-dioxa-1,3-diazadispiro [ 4.2.4.2] tetradecane-2,4-dione (II-1) with 9.8 molar equivalents of potassium hydroxide in the form of 30% potassium hydroxide solution. Subsequently, with conc. Hydrochloric acid adjusted to a pH of 5.2 to 5.3. After filtration, the filtrate is concentrated by azeotropic distillation with methanol to about half the volume.
  • radicals R 8 to R 12 have the meanings given above, suitable precursor.
  • M is sodium or potassium, can be obtained in a simple manner and high yield.
  • the present invention accordingly also provides a novel process (C) for the preparation of compounds of the general formula (XIX), which comprises reacting the hydantoin of the formula (II-1, 9,12-dioxa-1,3-diazadispiro [ 4.2.4.2] tetradecane-2,4-dione) with sodium hydroxide solution or potassium hydroxide solution under reflux and then isolating the resulting compound of general formula (XIX) by filtration.
  • the sodium or potassium hydroxide is used in amounts of 1 to 10 molar equivalents. Preference is given to using between 2 and 7 equivalents. If the sodium or potassium hydroxide is used in these amounts, the compound of the formula (XIX) precipitates out as a solid.
  • the amount of water is between 250 and 1500 mL per mole of hydantoin. Preference is given to using between 300 and 1000 ml per mole of hydantoin.
  • the reaction temperature is between 50 and 200 ° C. Preference is given to working between 80 and 150 ° C.
  • the reaction can also be carried out under reduced or elevated pressure.
  • the compounds of general formula (XIX) are isolated by simple filtration. They can be used according to analytical content determination without further purification instead of the free amino acids in the Schotten-Baumann reaction for the preparation of the compound (XV # ), at the same time also an equivalent base is saved, which represents a further advantage of this method.
  • M stands for sodium or potassium.
  • M stands for sodium
  • R 1 to R 6 and R 8 to R 12 have the meanings given above and the corresponding radicals R 1 to R 6 and R 8 to R 12 are identical at both positions of the compounds of general formulas (XVI) or (XVII), and n is 0 or 1 and is identical at both positions of the compounds of the general formulas (XVI) or (XVII), characterized in that a keto compound of the general formula (XVIII)
  • inert solvents can be used under the reaction conditions.
  • suitable solvents are, for example: dichloromethane, toluene, ortho, meta or para-xylene, mesitylene, chlorobenzene, ortho-dichlorobenzene, acetonitrile, butyronitrile, tetrahydrofuran, 2-methyl-tetrahydrofuran, cyclopentyl methyl ether, methyl tertiary butyl ether, tertiary amyl methyl ether, 1,4-dioxane or mixtures of these solvents.
  • ⁇ , ⁇ -diol of the general formula (XIV) is used in an amount of at least 2 mol, based on 1 mol of the compound of the general formula (XVIII). It is also possible to work in any excess of a, ra-diol of the general formula (XIV) and to use this simultaneously as a solvent.
  • the process (D) according to the invention is carried out in the presence of a catalytic amount of an acid.
  • suitable acids are: hydrogen chloride, sulfuric acid, methanesulfonic acid, trifluoromethanesulfonic acid, para-toluenesulfonic acid or acidic ion exchange resins such as, for example, amberlite. Sulfuric acid or para-toluenesulfonic acid is preferably used.
  • the acid is used in amounts of from 0.01 to 20% by weight, based on the compound of the general formula (XVIII). Preference is given to 0.05 to 10 percent by weight.
  • the inventive method (D) is carried out at temperatures between 20 and 150 ° C; preferably between 50 and 120 ° C.
  • R 1 to R 6 independently represent hydrogen, methyl, ethyl or phenyl and are identical at both positions of the compounds of the general formulas (XVI) or (XVII), n is 0 or 1 and at both positions of the compounds of the general formulas (XVI) or (XVII) is identical, and the leftovers
  • R 8 to R 12 are each independently hydrogen, methyl, ethyl, fluoroalkyl having one or 2 C atoms and one to five fluorine atoms, halogen, methoxy, ethoxy, trifluoromethoxy or optionally substituted by methyl, ethyl, methoxy, ethoxy or halogen substituted phenyl and at both positions of the compounds of the general formulas (XVI) or (XVII) are identical.
  • R 1 to R 6 are independently hydrogen or methyl and are identical at both positions of the compounds of general formulas (XVI) or (XVII), n is 0 and the radicals
  • R 8 to R 12 independently of one another represent hydrogen, methyl, ethyl, fluorine, chlorine, methoxy, ethoxy or optionally phenyl which is substituted by methyl, ethyl, methoxy, ethoxy, fluorine or chlorine and identical at both positions of the compounds of the general formulas (XVI) or (XVII).
  • R 10 is chlorine
  • Example 6 1-l- (4-Chloro-2,6-dimethylphenyl) -12-hydroxy-1,4-dioxa-9-azadispiro [4.2.4.2] tetradec-1-en-10-one (Ex. 1)
  • Example 14 1 - ⁇ [(4-Chloro-2,6-dimethylphenyl) acetyl] amino ⁇ -4-oxocyclohexanecarboxylic acid (Ex. XV-1)
  • Methyl 8-amino-1,4-dioxaspiro [4.5] decane-8-carboxylate To a suspension of 64.5 g of 8-amino-l, 4-dioxaspiro [4.5] decane-8-carboxylic acid in 960 ml of methanol are added dropwise at 5 to 10 ° C within 60 minutes 57 g of thionyl chloride. The mixture is heated to 40 to 45 ° C and stirred for 48 hours at this temperature. After cooling to 5 ° C, the solid is filtered off with suction, washed with 60 ml of cold methanol and dried.
  • a solution of 42.0 g crude methyl-8-amino-l, 4-dioxaspiro [4.5] decane-8-carboxylate hydrochloride, which is about 69% and additionally about 21% methyl-l-amino-4,4 -dimethoxycyclohexanecarboxylate, in 135 ml of water is cooled to 10 ° C and adjusted to a pH of about 7.2 with 1 N sodium hydroxide solution.
  • the bottom is allowed to cool to about 50 ° C and then sets 110 ml of ⁇ , ⁇ -dimethylacetamide to.
  • the xylene is then distilled off in a slight vacuum at a boiling point of about 70.degree. It is then cooled to 50 ° C and added dropwise within 10 minutes 36.47 g of 30% methanolic sodium methylate solution.
  • the mixture is heated to 70 ° C and distilled off within about 2 hours in a slight vacuum, the methanol.
  • the ⁇ , ⁇ -dimethylacetamide is largely distilled off in vacuo.
  • the residue is taken up in 500 ml of water and the solution is brought to a pH of about 5 by the addition of glacial acetic acid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP17749168.5A 2016-08-04 2017-07-31 Verfahren zur herstellung von spiroketal-substituierten cyclischen ketoenolen Pending EP3494109A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16182706 2016-08-04
PCT/EP2017/069287 WO2018024659A1 (de) 2016-08-04 2017-07-31 Verfahren zur herstellung von spiroketal-substituierten cyclischen ketoenolen

Publications (1)

Publication Number Publication Date
EP3494109A1 true EP3494109A1 (de) 2019-06-12

Family

ID=56686646

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17749168.5A Pending EP3494109A1 (de) 2016-08-04 2017-07-31 Verfahren zur herstellung von spiroketal-substituierten cyclischen ketoenolen

Country Status (10)

Country Link
US (1) US11220511B2 (ko)
EP (1) EP3494109A1 (ko)
JP (2) JP7128175B2 (ko)
KR (2) KR102466169B1 (ko)
CN (1) CN109563066B (ko)
BR (1) BR112019002192B1 (ko)
IL (1) IL264485B (ko)
MX (1) MX2019001465A (ko)
TW (1) TWI758308B (ko)
WO (1) WO2018024659A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019002192B1 (pt) * 2016-08-04 2022-11-16 Bayer Cropscience Aktiengesellschaft Processo para produzir cetoenóis cíclicos substituídos por espirocetal, e seus intermediários e seu processo de preparação
BR112020018374A2 (pt) * 2018-04-10 2020-12-29 Bayer Aktiengesellschaft Processos para preparação de ésteres de ciclohexano-aminoácidos substituídos, e seus intermediários cetoenóis cíclicos substituídos por espirocetal
AU2019250616A1 (en) * 2018-04-13 2020-10-29 Bayer Aktiengesellschaft Solid formulation of insecticidal mixtures
JP2021521157A (ja) * 2018-04-13 2021-08-26 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 油性懸濁液濃縮物
MA52187A (fr) * 2018-04-13 2021-02-17 Bayer Ag Formulation solide de melanges insecticides
IL277967B2 (en) * 2018-04-17 2023-10-01 Bayer Ag A method for the preparation of N-acylated amino acid esters with acid-labile ketone protecting group functions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225830C (en) 1995-06-30 2008-01-08 Bayer Aktiengesellschaft Dialkyl phenyl halide-substituted keto-enols for use as herbicides and pesticides
DE19742492A1 (de) 1997-09-26 1999-04-01 Bayer Ag Spirocyclische Phenylketoenole
FR2772762B1 (fr) * 1997-12-18 2000-05-26 Seranalis Procedes de preparation d'un derive d'hydantoine substituee en position 5, d'un sel alcalin d'acide alpha-amine a partir de ce derive d'hydantoine, d'esterification d'acides alpha-amines cycliques, et nouveaux acides alpha-amines
DE102005008021A1 (de) * 2005-02-22 2006-08-24 Bayer Cropscience Ag Spiroketal-substituierte cyclische Ketoenole
DE102006007882A1 (de) * 2006-02-21 2007-08-30 Bayer Cropscience Ag Cycloalkyl-phenylsubstituierte cyclische Ketoenole
WO2012110519A1 (de) 2011-02-17 2012-08-23 Bayer Cropscience Ag Substituierte 3-(biphenyl-3-yl)-8,8-difluor-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-one zur therapie und halogensubstituierte spirocyclische ketoenole
BR112019002192B1 (pt) * 2016-08-04 2022-11-16 Bayer Cropscience Aktiengesellschaft Processo para produzir cetoenóis cíclicos substituídos por espirocetal, e seus intermediários e seu processo de preparação

Also Published As

Publication number Publication date
IL264485A (en) 2019-02-28
JP2019524770A (ja) 2019-09-05
KR20220141901A (ko) 2022-10-20
IL264485B (en) 2021-08-31
US11220511B2 (en) 2022-01-11
TWI758308B (zh) 2022-03-21
BR112019002192B1 (pt) 2022-11-16
CN109563066A (zh) 2019-04-02
KR102466169B1 (ko) 2022-11-14
JP2022119980A (ja) 2022-08-17
WO2018024659A1 (de) 2018-02-08
CN109563066B (zh) 2023-08-29
BR112019002192A2 (pt) 2019-05-21
KR20190034582A (ko) 2019-04-02
US20190202837A1 (en) 2019-07-04
JP7128175B2 (ja) 2022-08-30
TW201811802A (zh) 2018-04-01
MX2019001465A (es) 2019-06-06

Similar Documents

Publication Publication Date Title
WO2018024659A1 (de) Verfahren zur herstellung von spiroketal-substituierten cyclischen ketoenolen
DE2337813B2 (de) Verfahren zur herstellung von monoacetalen aromatischer 1,2-diketone
EP0454624B1 (de) Verfahren zur Herstellung von 1,3-Diketonen
DE3043252A1 (de) Cyclische acetale von n-acylglutaminsaeure- (gamma) -semialdehyden, verfahren zu deren herstellung und ihre verwendung
EP0125506A1 (de) 5-(2,6-Dichlor-4-trifluormethyl-phenoxy)-2-nitrobenzaldehyd-diacetacylal
DE2708189C2 (de) Verfahren zur Herstellung von Phenylglyoxylsäureestern
EP3452446B1 (de) Verfahren zur herstellung von cis-alkoxysubstituierten spirocyclischen 1-h-pyrrolidin-2,4-dion- derivaten
EP0600835B1 (de) Verfahren zur Herstellung von Phenylessigsäureester-Derivaten
EP3301092A2 (de) Verfahren zur herstellung von spiroketal-substituierten phenylacetylaminosäureestern und spiroketal-substituierten cyclischen ketoenolen
EP1001929B1 (de) Verfahren zur herstellung von 3-cyano-2,4-dihalogen-5-fluor-benzoesäuren
EP0439745A2 (de) Verfahren zur Herstellung von 2-Chlor-5-methyl-pyridin
EP0183149A2 (de) Verfahren zur Herstellung von 4-Acyloxy-3-oxo-butter-säureestern
DE10019291C2 (de) 2-Alkoxy-5-methoxypyrimidine bzw. deren tautomere Formen sowie Verfahren zu deren Herstellung
EP0268964B1 (de) Verfahren zur Herstellung von 6-Hydroxy-3-pyridincarbonsäureestern
DE1141634B (de) Verfahren zur Herstellung von Dithiolphosphorsaeureestern
EP0114289B1 (de) Verfahren zur Herstellung von 2-Alkylthiomethyl-4-hydroxypyrimidinen
EP0056938A2 (de) Verfahren zur Herstellung von 3,6-disubstituierten 4-Amino-1,2,4-triazin-5-onen
EP0221494A1 (de) Verfahren zur Herstellung von Glykolsäureamiden
AT215417B (de) Verfahren zur Herstellung neuer N-Carbalkoxy- bzw. -aralkoxyalkyl-β-(3,4-dihydroxyphenyl)-β-hydroxyäthylamine und deren Salze
WO2019197231A1 (de) Verfahren zur herstellung von substituierten cyclohexanaminosäureestern und spiroketalsubstituierten cyclischen ketoenolen
WO2009000649A1 (de) Verfahren zur herstellung von 2-hydroxy-acetalen und den dazu korrespondierenden 2-hydroxyalkanalen
EP0678515A1 (de) Verfahren und Zwischenprodukte zur Herstellung von 5-Oxaspiro 2.4 heptan-6-on
EP0295598A1 (de) Verfahren zur Herstellung von N-Alkoxycarbonylmethyl-N-formyl-aminen und -anilinen
DE4008223A1 (de) Verfahren zur herstellung von ss-resorcylsaeurederivaten
AT500495A1 (de) Verfahren zur herstellung von acetamid-acetalen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED